May. 29 at 2:53 PM
$AMGN (
$CCXI )Update for ChemoCentryx investors.
A proposed
$69 million cash settlement has been submitted to the court for approval in a securities class action involving ChemoCentryx, Inc.
Investors who purchased or held
$CCXI common stock between November 25, 2019, and May 6, 2021, may be eligible to recover part of their losses. Current estimates place the recovery at approximately
$1.46 per share.
The lawsuit alleges that the company made misleading statements about the ADVOCATE clinical trial for avacopan, including concerns related to FDA feedback, steroid use, and potential liver safety issues that were not fully disclosed before the trial data became public in May 2021.
Investors who qualify can review the case details and submit a claim here: https://11th.com/cases/chemocentryx-investor-settlement